Rationale for the use of dexpanthenol drugs as part of the external therapy of dermatoses in children and adults

Impaired skin barrier plays a major role in the development of many skin diseases and conditions such as dry skin, sensitive skin, atopic dermatitis, contact dermatitis, etc. The topical therapy aims at not only suppressing the inflammatory response in the skin, but also at regenerating the destroyed protective epidermal lipid barrier in atopic dermatitis patients. Dexpanthenol was produced by synthesis in the middle of the last century and is a derivative of pantothenic acid. Topical dexpanthenol is well absorbed through the skin, where it is converted into pantothenic acid, a component of coenzyme A, and thus participates in the regulation of the synthesis of fatty acids and sphingolipids, components of the stratum corneum. Therefore, pantothenic acid is essential for the normal functioning of the epithelium. Topical dexpanthenol improves skin hydration due to its hygroscopic properties and ability to retain moisture. The hydrating effect is interrelated with its capacity to regenerate the epidermal barrier of the skin. Dexpanthenol also enhances the differentiation of corneocytes and lipid synthesis, stimulating the regeneration of the epidermis. Numerous studies show that the efficacy of dexpanthenol is comparable to the efficacy of glucocorticosteroids by a weak degree of activity. Dexpanthenol is the active ingredient of Pantoderm, which is available as cream and ointment. Pantoderm ointment and cream contain 5% dexpanthenol. The article presents its own clinical reports of the treatment of patients with atopic dermatitis and administration of the combination therapy. It may be concluded that the use of topical glucocorticosteroids combined with dexpanthenol can increase the effectiveness of therapy in patients with atopic dermatitis.

1. Kelly G.S. Pantothenic acid. Monograph. Altern Med Rev. 2011;16:263-274. https://pubmed.ncbi.nlm.nih.gov/21951027/.

2. Lanska D.J. The discovery of niacin, biotin, and pantothenic acid. Ann Nutr Metab. 2012;61(3):246-253. https://doi.org/10.1159/000343115.

3. Stuttgen G., Krause H. Die percutane absorption von tritium-markiertem panthenol bei mensch und tier. Arch Klin Exp Derm. 1960;209:578-82. https://doi.org/10.1007/BF00477492.

4. Wollina U., Kubicki J. Multiaktive eigenschaften von dexpanthenol-haltigen externa. Kosm Med. 2007;28:122-128. Available at: https://www.researchgate.net/publication/263278521_Multiaktive_Eigenschaften_von_Dexpanthenol-haltigen_Externa.

5. Abiko Y., Tomikawa M., Shimizu M. Enzymatic conversion of pantothenylalcohol to pantothenic acid. J Vitaminol (Kyoto). 1969;15(1):59-69. https://doi.org/10.5925/jnsv1954.15.59.

6. Proksch E., Jensen J.M. Dexpanthenol. In Barel A.O., Paye M., Maibach H.I., ed. Handbook of Cosmetic Science and Technology. 2nd ed. New York, London: Taylor & Francis Group; 2006, p. 399-406. https://doi.org/10.1201/b14400.

7. Proksch E., Holleran W.M., Menon G.K., Elias P.M., Feingold K.R. Barrier function regulates epidermal lipid and DNA synthesis. Br J Dermatol. 1993;128(5):473-482. https://doi.org/10.1111/j.1365-2133.1993.tb00222.x.

8. Slyshenkov V.S., Rakowska M., Moiseenok A.G., Wojtczak L. Pantothenic acid and its derivatives protect Ehrlich ascites tumor cells against lipid peroxidation. Free Radic Biol Med. 1995;19(6):767-772. https://doi.org/10.1016/0891-5849(95)00084-B.

9. Proksch E., Nissen H.P. Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphate-induced irritation. J Dermatolog Treat. 2002;13(4):173-178. https://doi.org/10.1080/09546630212345674.

10. Wollina U. Zur klinischen wirksamkeit von dexpanthenol. Kosm Med. 2001;22:180-186. Available at: https://www.researchgate.net/publication/263278358_Zur_klinischen_Wirksamkeit_von_Dexpanthenol.

11. Eggensperger H. Multiaktive Wirkstoffe fur Kosmetika: Teil II. Seifen Ole Fette Wachse J. 1994;120(9):534-538. Available at: https://www.econbiz.de/Record/multiaktive-wirkstoffe-f%C3%BCr-kosmetika-teil-ii-eggensperger/10006801140.

12. Verse T., Klocker N., Riedel F., Pirsig W., Scheithauer M.O. Dexpanthenol - Nasenspray vs. Nasensalbe. HNO. 2004;52:611-615. https://doi.org/10.1007/s00106-003-0961-4.

13. Abdel Hamid M., Kassem A.A., Mattha A.G., El-Khatib G. Evaluation of the biological activity of some medicated solidified sodium stearate-based sticks (SSSS). Drug Dev Ind Pharm. 1984;(10):685-697. https://doi.org/10.3109/03639048409041415.

14. Hauptmann S., Schafer H., Fritz A., Hauptmann P. The growth modifying effect of wound ointments on cell cultures. Hautarzt. 1992;43(7):432-435. Available at: https://pubmed.ncbi.nlm.nih.gov/1506201.

15. Pittermann W., Schmitt M., Kietzmann M. Skin penetration properties of cosmetic formulations using a perfused bovine udder model. J Cosmet Sci. 1999;50(3):147-157. Available at: https://www.researchgate.net/publication/237400255_Skin_penetration_properties_of_cosmetic_formulations_using_a_perfused_bovine_udder_model.

16. Loden M. Treatments Improving Skin Barrier Function. Curr Probl Dermatol. 2016;49:112-122. https://doi.org/10.1159/000441586.

17. Bensaude A. Treatment of anal fissure. Phlebologie. 1980;33(4):683-688. Available at: https://pubmed.ncbi.nlm.nih.gov/7454838/.

18. Loden M. Treatments improving skin barrier function. Curr Probl Dermatol. 2016;49:112-122. https://doi.org/10.1159/000441586.

19. Bjorklund S., Pham Q.D., Jensen L.B., Knudsen N.0., Nielsen L.D., Ekelund K. et al. The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016;479:207-220. https://doi.org/10.1016/j.jcis.2016.06.054.

20. Gimenez-Arnau A. Standards for the protection of skin barrier function. Curr Probl Dermatol. 2016;49:123-134. https://doi.org/10.1159/000441588.

21. Gehring W., Gloor M. Effect of topically applied dexpanthenol on epidermal barrier function and stratum corneum hydration. Results of a human in vivo study. Arzneimittelforschung. 2000;50(7):659-663. https://doi.org/10.1055/s-0031-1300268.

22. Al-Momani T., Tawalbeh A., Shatnawi M., Tarawneh H., Sharadgah Z. Napkin dermatitis in babies: characteristics and efficacy of panthenol treatment. WJPMR. 2016;(2):22-24. Available at: https://www.wjpmr.com/home/article_abstract/50.

23. Putet G., Guy B., Pages S., Gibaud C., Andres P., Sirvent A. et al. Effect of Bepanthen Ointment in the Prevention of Diaper Rash on Premature and Full-Term Babies: Open Pilot Study. Real Pediatr. 2000;52:21-28. Available at: https://www.huidherstel-pro.nl/studies/detail/effect-of-bepanthen-ointment-in-the-prevention-of-diaper-rash-on-premature-and-full-term-babies-open-pilot-study

24. Putet G., Guy B., Andres P., Sirvent A. Effect of BepanthenVR ointment in the prevention and treatment of diaper rash onpremature and full-term babies. Real Pediatr. 2001;63:33-38. Available at: https://www.researchgate.net/publication/285312774_Effect_of_Bepanthen_ointment_in_the_prevention_and_treatment_of_diaper_rash_on_premature_and_full-term_babies.

25. Wolff H.H., Kieser M. Hamamelis in children with skin disorders and skin injuries: results of anobservational study. Eur J Pediatr. 2007;166(9):943-948. https://doi.org/10.1007/s00431-006-0363-1.

26. Biro K., Thaci I.D., Ochsendorf F.R., Kaufmann R., Boehncke W.-H. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003;49(2):80-84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.

27. Gehring W., Gloor M. Der repetitive waschtest als modell zur beurteilung von hautschutzpraparaten am beispiel einer dexpanthenolhaltigen formulierung. Akt Dermatol. 2001;27(8/9):279-284. https://doi.org/10.1055/s-2001-17290.

28. Gehring W., Gloor M. Der effekt von dexpanthenol bei experimentell geschadigter haut. Z Hautkr. 2001;76(4):212-218. Available at: https://www.researchgate.net/publication/287423763_The_effect_of_dexpanthenole_in_experimentally_damaged_skin.

29. Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol. 2008;21(2):75-80. https://doi.org/10.1159/000112957.

30. Biro K., Thaci I.D., Ochsendorf F.R., Kaufmann R., Boehncke W.-H. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003;49(2):80-84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.

31. Simpson E.L., Berry T.M., Brown P.A., Hanifin J.M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. https://doi.org/10.1016/j.jaad.2009.11.011.

32. Stettler H., Kurka P., Kandzora J., Pavel V., Breuer M., Macura-Biegun A. A new topical panthenol-containing emollient for maintenance treatment of childhood atopic dermatitis: Results from a multicenter prospective study. J Dermatol. Treat. 2017;28(8):774-779. https://doi.org/10.1080/09546634.2017.1328938.

33. Stables G.I., Wilkinson S.M. Allergic contact dermatitis due to panthenol. Contact Dermatitis. 1998;38(4):236-237. https://doi.org/10.1111/j.1600-0536.1998.tb05732.x.

34. Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol. 2008;21(2):75-80. https://doi.org/10.1159/000112957.

35. Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2O12;26(8):1O45-1060. https//doi.org/10.1111/j.1468-3083.2012.04635.x.

36. Simpson E.L., Berry T.M., Brown P.A., Hanifin J.M. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587-593. https//doi.org/10.1016/j.jaad.2009.11.011.

37. Simpson E.L., Chalmers J.R., Hanifin J.M., Thomas K.S., Cork M.J., McLean W.H.I. et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-823. https://doi.org/10.1016/j.jaci.2014.08.005.

38. Udompataikul M., Limpa-O-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366-374. Available at: https//pubmed.ncbi.nlm.nih.gov/22395588/.

39. Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. https//doi.org/10.1111/jdv.14891.

40. Kubanov A.A., Namazova-Baranova L.S., Khaitov R.M., Il'ina N.I., Ambarchyan E.T., Arshinskiy M.I. et al. Atopic dermatitis: clinical guidelines. 2020. (In Russ.) Available at: https://www.nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf.

41. Chikin V.V., Znamenskaya L.F., Monakhov K.N., Zaslavskiy D.V., Mineeva A.A., Epishev R.V. et al. Russian Association of Allergists and Clinical Immunologists: federal clinical guidelines for the diagnosis and treatment of atopic dermatitis.. 2013. (In Russ.) Available at: https://mzdrav.rk.gov.ru/file/Atopicheskij_dermatit_05052014_Klinicheskie_rekomendacii%281%29.pdf.

42. Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberger K. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. https://doi.org/10.1016/j.jaad.2014.03.023.

43. Udompataikul M., Limpa-O-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366-374. Available at: https://pubmed.ncbi.nlm.nih.gov/22395588/.

44. Chiricozzi A., Belloni Fortina A., Galli E., Girolomoni G., Neri I., Ricci G. et al. Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel. Allergol Immunopathol. 2019;47(2):194-206. https://doi.org/10.1016/j.aller.2018.06.008.

45. Harcharik S., Emer J. Steroid-sparing properties of emollients in dermatology. Skin Therapy Lett. 2014;19(1):5-10. Available at: https://pubmed.ncbi. nlm.nih.gov/24570291/.

46. Ebner F., Heller A., Rippke F., Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427-433. https://doi.org/10.2165/00128071-200203060-00005.

47. Bielfeldt S., Wehmeyer A., Rippke F., Tausch I. Efficacy of a New Hand Care System (Cleansing Oil and Cream) in a Model of Irritation and by Atopic Hand Eczema. Derm Beruf Umwelt. 1998;46:159-165. Available at: https://chemport-n.cas.org//chemport-n/?APP=ftslink&action=reflink&-origin=npg&version=1.0&coi=1%3ACAS%3A528%3ADyaK1cXmtFCrur8%3D&md5=5737368d83b27b3c0b61a92055d19c92.

48. Siegfried E.C., Jaworski J.C., Kaiser J.D., Hebert A.A. Systematic review of published trials: Long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75. https://doi.org/10.1186/s12887-016-0607-9.

49. Czarnowicki T., He H., Krueger J.G., Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11. https://doi.org/10.1016/j.jaci.2018.10.032.

50. Tokura Y., Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype. Allergol Int. 2022;71(1):14-24. https://doi.org/10.1016/j.alit.2021.07.003.

51. Piquero-Casals J., Carrascosa J.M., Morgado-Carrasco D., Narda M., Trullas C., Granger C., Fabbrocini G. The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis. Dermatol Ther. 2021;11(2):315-325. https://doi.org/10.1007/s13555-021-00495-y.

52. Luk D., Hon K.L.E., Dizon M.V.C., Leong K.F., Tay Y.K., Koh M.J. et al. Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia. Dermatol Ther. 2021;11(1):275-291. https://doi.org/10.1007/s13555-020-00467-8.